Clinical trial
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With…
NCT05108922 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT05108922 |
|---|---|
| Title | A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) |
| Official title | A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mild Cognitive Impairment (MCI), Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Donanemab, Aducanumab |
| Enrollment | 148 |
| Start date | Nov 16, 2021 |
| Primary completion | Sep 9, 2022 |
| Completion | Sep 19, 2023 |
| First posted | Nov 5, 2021 |
| Last update posted | Nov 29, 2024 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: